Marie C. Hogan, M.D., Ph.D.

The purpose of this study is to examine patient reported outcomes including pain, quality of life, depression and impact on kidney blood flow before and after procedure to destroy the pain sensory nerves of the kidneys in patients with untreatable one or two sided kidney pain. We will also collect retrospective data on patientsn who underwent the procedure as clinical care but did not particiapte in the prospective study. 

Statistical recording and characterization of a patient cohort with clinical or molecular diagnosis of polycystic liver or kidney disease (PLD/PKD). (2) Evaluation of patient reported outcomes in response to clinical interventions. Characterization of phenotypic severity, including liver volumes from available cross-sectional imaging (MRI/CT). Implementation of PLD-Q to evaluate the patient reported outcomes.

The RPD Pilot trial will evaluate the safety and effectiveness of Verve Medical's RPDTM renal denervation system for hypertensive patients with uncontrolled blood pressure, despite use of two anti-hypertensive medications and lifestyle changes. The novelty of the RPDTM system relates to its placement via natural orifice into the pelvis of the kidney (bilaterally) for delivery of radiofrequency energy to ablate the nerves that pass through the outer wall of the renal pelvis, a technique referred to as renal pelvic denervation (RPD).

This is a study where a new drug, called GSK4771261 is being tested. Neither the study doctors, study staff or participants will be aware of what treatment is being given. Part A is testing the new study treatment on healthy people. This is to see if it's safe, what it does to the body, and how the body's defense system responds to it. Part B is similar, but the study treatment will be given to people who have a kidney disease called autosomal dominant polycystic kidney disease (ADPKD).

The purpose of ths study is to assess the safety and tolerability of RGLS8429. Addiitionally, to assess the impact of RGLS8429 on ADPKD biomarkers

Other objectives are o assess the impact of RGLS8429 on height-adjusted total kidney volume (htTKV) and to characterize the pharmacokinetic (PK) properties of RGLS8429 -To assess the impact of RGLS8429 on renal function.

The purpose of this study is to compare SOM230 treatment to placebo. The investigators will also assess the efficacy and safety of SOM230 in reducing total liver volume and improving quality of life.

The purpose of this trial is to evaluate the effectiveness and safety of 2 treatment regimens of CAM2029 versus placebo in patients with Polycystic Liver Disease (PLD). 

This research study is about developing a rapid, accurate urine test to help diagnose and perhaps monitor ADPKD (Autosomal Dominant Polycystic Kidney Disease).

The purpose of this study is to investigate the biological variation in baseline levels of proteins (uELV PC1 and PC2) in individual Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients within a 14 day period that will enable the further optimization of biomarker assays for measuring uELV PC1 and PC2.

This Pilot study will enable development & assessment of a Polycystic Liver Disease-specific patient reported outcomes questionnaire (PLD-Q). Polycystic liver disease (PLD) is characterized by the formation of numerous cysts in the liver, and can lead to severe symptomatic hepatomegaly. It is common in patients with autosomal dominant polycystic liver disease (ADPLD) and autosomal dominant polycystic kidney disease (ADPKD).

The purpose of this study is to determine whether the source of urinary CD80 and CD163 and other biomarkers elevated in Nephrotic Syndrome is from renal cells or a subset of circulating white blood cells. Also, the study aims to determine whether CD80 and CD163 and other biomarkers levels can predict disease response to treatment.

The purpose of this study is to develop urine tests that will measure biological markers and use them to track the status of kidney disease. This test may help doctors to better care for patients with kidney disease.

The purpose of this study is to determine the impact of foam sclerotherapy of large, dominant kidney/liver cysts on quality of life outcomes and kidney/liver cyst volumes at up to 12 months of follow-up in patients with autosomal dominant polycystic kidney disease (ADPKD) and autosomal dominant polycystic liver disease (ADPLD).
 

The purpose of this study is to evaluate and better understand the natural history, clinical characteristics and outcomes of Nephronophthisis, a genetically linked kidney disease that progresses to end stage before the age of 30.

The purpose of this study approach aims to identify exomic alterations that contribute to the development of kidney disease.